Johnson & Johnson has made an offer of nearly $9 billion to try to resolve tens of thousands of lawsuits it faces in the US that claim its talc products cause cancer.&
Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treatment availab
The Association of the British Pharmaceutical Industry (ABPI) has added five new patient organisation figures to its patient advisory council, set up to provide patient pe
Johnson & Johnson’s attempt to draw a line under the ongoing litigation it faces over allegations that its talc products cause cancer has been blocked by an appeals co
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t
Sword Health has extended its range of digital interventions for health conditions with the launch of an artificial intelligence-powered programme that can help predict wh